

Contact Carl Berke For More Information Carl@Berkesearch.com

- **04.21.23 - Genalyte Announces Expansion of its Series C to over \$67 million led by Verily Life Sciences & Boutique Venture Partners (PR)**
 - Genalyte, Inc., a leading diagnostics and analytics company, announced that it has closed on the expansion of its Series C financing to include an additional \$17.5 million for a total of over \$67 million, led by Verily Life Sciences (an Alphabet company) and Boutique Venture Partners (a specialized healthcare fund). Along with Boutique and Verily, this financing round also included current investors Redmile Group, Provenio Capital, HBM Healthcare Investments, Khosla Ventures, Samsara Biocapital, and Invus.
- **04.20.23 - Enveda Biosciences Announces Oversubscribed Series B1 Bringing Total Round to US\$119 Million (PR)**
 - Enveda is a drug discovery and development company using the latest AI-powered technologies to uncover the ancient cache of medicines present in plants. The company's proprietary platform solves the long-standing obstacles in natural product drug development including active molecule identification, property and structure prioritization, amenability to medicinal chemistry, and large-scale material access. The additional financing will enable Enveda to progress multiple platform-derived molecules to the clinic in 2023 and 2024 across inflammation, fibrosis, and neurosensory indications. The \$51M equity financing to add to the \$68 million Series B announced in December 2022. Kinnevik led the Series B1 round, which also included participation by new investor Henry R. Kravis, the Co-Founder and Co-Executive Chairman of KKR. The round included strong participation from Enveda's current major investors, including FPV, True Ventures, Dimension, and Wireframe.
- **04.20.23 - Abdera Therapeutics Debuts With \$142M in Financing to Engineer and Advance Best-in-Class Antibody-Based Radiopharmaceuticals for Cancer (PR)**
 - Proprietary ROVER™ platform enables design of next-generation radiopharmaceuticals with tunable pharmacokinetic (PK) properties to maximize therapeutic effect and mitigate systemic toxicities. Potential for alpha- or beta-emitting radiopharmaceuticals, for clinically validated and novel cancer targets with a wide range of antigen expression. Lead program targeting DLL3 for small cell lung cancer and other solid tumors advancing toward clinic. Investor syndicate includes Versant Ventures, venBio Partners, Amplitude Ventures, adMare BioInnovations, Viking Global Investors, Qiming Venture Partners USA, RTW Investments, AbCellera and Northview Ventures
- **04.19.23 - Gamida Cell Raises \$23 Million in Public Offering to Support Launch of Newly Approved Cell Therapy (PR)**
 - Two days after the U.S. Food and Drug Administration approved its allogeneic cell therapy, Omisirge, Gamida Cell priced of an underwritten public offering of 17.5 million shares and accompanying warrants to purchase 17.5 million shares at a public offering price of \$1.30 per share and accompanying warrant, for gross proceeds of approximately \$22.8 million, before deducting underwriting discounts and commissions and estimated offering expenses. Gamida Cell intends to use the net proceeds from this offering, together with its existing capital to fund commercialization activities to support the launch of its newly approved allogeneic cell therapy Omisirge; to continue clinical development of pipeline candidate GDA-201, an intrinsic NK cell therapy candidate being investigated for the treatment of hematologic malignancies; and for general corporate purposes.
- **04.19.23 - CIRM commits \$60 million for Parkinson's research, joins #Take6ForPD awareness campaign (PR)**
 - April is Parkinson's Awareness Month and the California Institute for Regenerative Medicine (CIRM) is joining the campaign to #Take6ForPD—take 6 minutes to raise Parkinson's awareness and highlight our commitment to funding research for the disease. To date, CIRM has invested more than \$60 million in helping research for PD progress from a basic or Discovery level through clinical trials. This year, CIRM awarded \$4 million to a late-stage preclinical project by Ryne Bio aiming to improve treatment for idiopathic PD. In the proposed stem cell therapy, investigators at Ryne Bio are aiming to deliver dopamine-producing cells to replace the lost neurons to the brain of PD patients to restore or improve motor function.
- **04.17.23 - Complement Therapeutics Secures €72 Million in Series A Financing to Advance Novel Therapies Targeting Complement-Mediated Diseases (PR)**
 - Round led by Gimv, a Belgian based private equity and venture capital firm, With this new round of financing, CTx will continue the development and complete a Phase Ib clinical proof of concept of its lead product CTx001. CTx001 is a highly innovative AAV gene therapy for the treatment of Geographic Atrophy (GA) secondary to dry age-related macular degeneration (dry-AMD). Additionally, proceeds from this financing will be deployed to grow its laboratory-based activities in Stevenage (UK), evaluate CTx's pipeline assets for non-ocular indications as well as further develop the novel Complement Precision Medicine (CPM) platform. Round comes just 1 year after raising €5 million seed funding in February 2022. Company aims to transform the treatment of complement mediated conditions
-